Evidence map›Paper›PMID 42279246›Full record

ArticleJournal of clinical medicine2026

Expression of PD-L1 and PD-L2 and Their Association with IFN-γ/STAT1/STAT3 Signaling in Human Clear Cell Renal Cell Carcinoma (ccRCC).

Gábor Kónya, Ali Shammas, Erzsébet Szabó, Róbert Tupicza, Seyed Behrad Piran, Krisztián Szegedi, Anna Vass, Éva Juhász, József Király, Balázs Dezső and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Gábor KónyaDepartment of Biopharmacy, Faculty of Pharmacy, University of Debrecen, 4002 Debrecen, Hungary.ORCID 0000-0003-3759-428X
Ali ShammasDepartment of Biopharmacy, Faculty of Pharmacy, University of Debrecen, 4002 Debrecen, Hungary.
Erzsébet SzabóDepartment of Pharmacology, Faculty of Pharmacy, University of Debrecen, 4002 Debrecen, Hungary.
Róbert TupiczaDepartment of Pharmacology, Faculty of Pharmacy, University of Debrecen, 4002 Debrecen, Hungary.
Seyed Behrad PiranDepartment of Biopharmacy, Faculty of Pharmacy, University of Debrecen, 4002 Debrecen, Hungary.ORCID 0009-0008-6269-9394
Krisztián SzegediDepartment of Urology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.ORCID 0000-0003-4311-9936
Anna VassDepartment of Biopharmacy, Faculty of Pharmacy, University of Debrecen, 4002 Debrecen, Hungary.
Éva JuhászDepartment of Pediatrics, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
József KirályDepartment of Biopharmacy, Faculty of Pharmacy, University of Debrecen, 4002 Debrecen, Hungary.
Balázs DezsőDepartment of Pathology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
Mahua ChoudhuryDepartment of Pharmaceutical Sciences, Irma Lerma Rangel School of Pharmacy, Texas A&M Health Science Center, College Station, TX 77845, USA.
Zsuzsanna SzabóDepartment of Biopharmacy, Faculty of Pharmacy, University of Debrecen, 4002 Debrecen, Hungary.
Gábor HalmosDepartment of Biopharmacy, Faculty of Pharmacy, University of Debrecen, 4002 Debrecen, Hungary.

Funding

Ministry for Innovation and Technology GINOP-2.3.2-15-2016-00043Ministry for Innovation and Technology TKP2021-EGA-20
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

ccRCCIFN-γ signalingimmune checkpointPD-1PD-L1PD-L2STAT1STAT3TME

Identifiers

PMID42279246
PMCPMC13258552

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.